CliffBio
small molecule

HALAVEN

ERIBULIN MESYLATE

Loss of exclusivityJuly 2027latest FDA-listed patent expiry
CompanyEisai →See this company's full patent-cliff portfolio

Drug detail

Brand nameHALAVEN
Active ingredientERIBULIN MESYLATE
Strength1MG/2ML (0.5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2010
Marketing statusRX

Listed patents

PatentExpiresType
RE46965*PEDJuly 2027—
RE46965January 2027product

Regulatory exclusivity

CodeExpires
PEDMarch 2026
M-280September 2025

More from Eisai

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

HALAVEN patent cliff — loss of exclusivity July 2027 | CliffBio